Pausing the New Zealand Medical Products Bill is necessary to ensure that such a significant piece of legislation is built on broad consensus, not limited input. As it stands, many stakeholders including practitioners, industry groups, and consumers have raised concerns about the scope, complexity, and potential unintended consequences of the Bill. Rushing it through without fully addressing these issues risks creating a regulatory framework that is overly restrictive, poorly understood, and ultimately counterproductive to public health and innovation. A pause would allow time to properly assess the impacts, clarify intent, and ensure that the legislation is proportionate and fit for purpose.
Restarting consultation would restore trust and transparency in the process. Effective health regulation depends on the confidence and cooperation of those it affects, and that can only be achieved through genuine, inclusive engagement. By reopening consultation, the Government can ensure that diverse perspectives are heard particularly from those working on the front lines of healthcare and natural health. This would lead to more balanced, practical legislation that protects consumer safety while supporting choice, innovation, and access. In the long term, taking the time to get this right will result in a stronger, more durable regulatory system for New Zealand.